Policy
The needs and consequences of the rapidly aging population continue to dominate health and social policies on the federal level. The Alliance for Aging Research plays a major role in informing and shaping the efforts of policymakers as the debate over these policies takes place. For the past 20 years, the Alliance for Aging Research has been committed to advancing scientific discoveries to improve the experience of aging. The Alliance will continue this mission while also serving as an objective “anti-silo” player in the area of healthy aging research – seeking to clear legislative and regulatory obstacles that impede progress.
- Access to Breakthroughs
- Drug Development
- Drug Safety
- Federal Funding
- Geriatric Training
- Regenerative Medicine
Related Publications
-
Press ReleaseAlliance Releases The Silver Book®: Diabetes
The Alliance for Aging Research released a new volume of The Silver Book®: Chronic Disease and Medical Innovation in an Aging Nation. The latest addition to The Silver Book series focuses on diabetes. The volume was released at a Capitol Hill briefing which featured medical and economic experts and a patient advocate. The briefing was co-sponsored by the American Diabetes Association. -
Get Mad ColumnCAN You Help Find a Cure?: Funding May Mean the Difference Between Life and Death
Spring 2010 | Alliance for Aging Research
Related topics: Access to Breakthroughs Drug Development Federal Funding Medical Innovation PolicyAfter a long fought battle over how best to structure meaningful health reform legislation, President Obama signed the Patient Protection and Affordable Care Act into law in March. Many media sources are reporting on the negative financial impact some health reform provisions might have on the country, but little attention has been focused on positive aspects of the bill that could make a real difference in the lives of many people suffering from, or who will face, serious and life-threatening illnesses. -
Document, TestimonyAlliance President Makes Remarks at a Hearing on Prescription Drug User Fee Act Reauthorization
On April 12th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the reauthorization process for the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public.
